Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Janssen Introduces AKEEGA™ First Dual Action Tablet for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Janssen has introduced AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet.

This innovative dual action tablet (DAT) combines two distinct therapeutic mechanisms: niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, an androgen biosynthesis inhibitor.

AKEEGA™ (niraparib and abiraterone acetate) marks a significant advancement in the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA gene alterations.

AKEEGA™ offers hope for improved outcomes and survival for individuals with mCRPC and BRCA-positive mutations, addressing a previously unmet medical need.

This unique combination targets two critical drivers of cancer growth in patients with mCRPC and BRCA-positive mutations. 

The approval of AKEEGA™ signifies a notable addition to the available treatment options for individuals with mCRPC. This advancement highlights the importance of personalized medicine and genetic testing in the field of oncology, particularly for prostate cancer patients.

Prostate cancer is a prevalent cancer type in the United States, with a considerable number of new cases and deaths projected for 2023. This underscores the urgent need for effective treatment strategies, especially for patients with aggressive forms of the disease, such as those with BRCA gene alterations.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024